5-amino-1mq tirzepatide stack Semaglutide vs vs AOD-9604: Three Different Fat Loss Mechanisms Compared AOD-9604 Clinical Trial Results Laboratory Chemical Size:5mg

5-amino-1mq tirzepatide stack Semaglutide vs vs AOD-9604: Three Different Fat Loss Mechanisms Compared AOD-9604 Clinical Trial Results Laboratory Chemical Size:5mg

AOD-9604 Clinical Trial Results & FDA Status (2026)

The trade-off is that Tesamorelin’s approval is narrow: it applies specifically to HIV-associated lipodystrophy, not general fat loss, and its GH-axis mechanism carries monitoring requirements around IGF-1 and glucose that AOD-9604’s trials did not show

Laboratory Chemical

Size:5mg

But the study authors named it explicitly as an off-target activity they are working to engineer out, and even speculated that some of the glucose-tolerance benefit might come from it